A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION

STUDY GOAL: To determine whether investigational ixazomib maintenance therapy improves survival in patients with newly diagnosed multiple myeloma who have had a major response to initial therapy and who have not had a stem cell transplant.

Learn more about this study

YOU MAY BE ELIGIBLE
TO PARTICIPATE IF YOU:

  • Are newly diagnosed with multiple myeloma (MM)
  • Have received initial therapy for 6 to 12 months and achieved a major response
  • Have not had a stem cell transplant
  • Are 18 years of age or older
  • Meet other eligibility criteria
LEARN MORE ABOUT ELIGIBILITY CRITERIA

ABOUT MULTIPLE
MYELOMA

An overview of the condition,
its symptoms, and
whom it affects.

GO

WHAT IS A
CLINICAL STUDY?

Learn about the purpose
of clinical studies, how
they are set up, and
why they are important.

GO
To learn more about
this study, call:
1-844-662-8532
Monday–Friday 9am–7pm ET

After hours?

Provide your contact information and we'll call you back.